Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer
Vivek Nimgaonkar, Eric A. Collisson(City College of San Francisco), Ekin Tiu, Vrishab Krishna(Vale (Brazil)), Zev A. Wainberg(University of California, Los Angeles), Aatur D. Singhi(University of California, San Francisco), Andrew Hendifar(Cedars-Sinai Medical Center), Christos Fountzilas(Roswell Park Comprehensive Cancer Center), Shalini Makawita(The University of Texas MD Anderson Cancer Center), Viswesh Krishna(Vale (Brazil)), Benjamin Musher(Baylor College of Medicine), Damir Vrabac(University of Pittsburgh Medical Center), Julia S. Johansen(ScienceScope (United Kingdom)), Katelyn Smith(Baylor College of Medicine), Davendra Sohal(University of Cincinnati), Hriday P. Bhambhvani(University of Copenhagen), Arnav Mehta(California Institute of Technology), Anirudh Joshi, Pranav Rajpurkar(Harvard University)
Cited by 19
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Genome-wide cell-free DNA fragmentation in patients with cancer
|Nature|2019|1.5k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet Oncology|2023|614
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
|The Lancet Oncology|2020|541
Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients
|Nature Communications|2015|484